

SARS-Related Coronavirus 2, Isolate USA/CA_CDC_5574/2020, Heat Inactivated

Catalog No. NR-55245

For research use only. Not for use in humans.

Contributor:

Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Manufacturer:

BEI Resources

Product Description:

NR-55245 is a preparation of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), isolate USA/CA_CDC_5574/2020 that has been inactivated by heating to 65°C for 30 minutes and diluted prior to vialing.

SARS-CoV-2, isolate USA/CA_CDC_5574/2020 was isolated from a nasopharyngeal swab on December 29, 2020 in San Diego County, California, USA.^{1,2}

Under the nomenclature system introduced by GISAID (Global Initiative on Sharing All Influenza Data), SARS-CoV-2, isolate USA/CA_CDC_5574/2020 is assigned lineage B.1.1.7 and GISAID clade GR using Phylogenetic Assignment of Named Global Outbreak LINEages (PANGOLIN) tool.^{2,3,4} The complete genome of SARS-CoV-2, isolate USA/CA_CDC_5574/2020 has been sequenced (GISAID: EPI_ISL_751801).^{1,2}

Material Provided:

Each vial contains approximately 0.25 mL of heat inactivated, clarified and diluted cell lysate and supernatant from Vero E6 cells infected with SARS-CoV-2, isolate USA/CA_CDC_5574/2020. The vial should be centrifuged prior to opening.

Note: The long-term stability of this preparation is not known at this time. It is recommended that users confirm the activity of the product if not used within three months of receipt. You may also contact BEI Resources for updated stability information.

Packaging/Storage:

NR-55245 was packaged aseptically in screw-capped plastic cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Citation:

Acknowledgment for publications should read “The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH:

SARS-Related Coronavirus 2, Isolate USA/CA_CDC_5574/2020, Heat Inactivated, NR-55245.”

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. This product is not intended for human use.

Use of this product is subject to the terms and conditions of the Emergency Use Simple Letter Agreement (EUSLA) and the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

SARS-CoV-2 materials provided by BEI Resources under the EUSLA are made available for any legitimate purpose, including commercial purposes as long as they are to rapidly prevent, detect, prepare for, and respond to, the spread or transmission of the 2019 SARS-CoV-2. Any further transfer of the original material or any unmodified progeny must be done under the terms of the EUSLA, documented as described above and you must notify BEI Resources of each subsequent transfer. Any new materials made by you that are not the original material or unmodified progeny are excluded from this requirement and you are free to share and commercialize those as your materials.

References:

1. Thornburg, N., Personal Communication.
2. [GISAID](https://gisaid.org/)

3. Rambaut, A., et al. "A Dynamic Nomenclature Proposal for SARS-CoV-2 Lineages to Assist Genomic Epidemiology." Nat. Microbiol. 5 (2020): 1403-1407. PubMed: 32669681.
4. Mercatelli, D. and F. M. Giorgi. "Geographic and Genomic Distribution of SARS-CoV-2 Mutations." Front. Microbiol. (2020): doi.org/10.3389/fmicb.2020.01800. PubMed: 32793182.

ATCC® is a trademark of the American Type Culture Collection.

